U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Structurally Diverse
Created
by admin
on Fri Jun 25 20:35:48 UTC 2021
Edited
by admin
on Fri Jun 25 20:35:48 UTC 2021
Source Materials Class ORGANISM
Source Materials Type VIRUS
Source Materials State LIVE
Organism Family Coronaviridae
Organism Genus Betacoronavirus
Organism Species Severe acute respiratory syndrome-related coronavirus
Author NONE
Infraspecific Type STRAIN
Infraspecific Name SARS-CoV-2
Part WHOLE
Record UNII
B6L4N5Z4GH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SARS-COV-2
Common Name English
COVID-19
Common Name English
2019-NCOV
Common Name English
SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
Common Name English
Code System Code Type Description
FDA UNII
B6L4N5Z4GH
Created by admin on Fri Jun 25 20:35:48 UTC 2021 , Edited by admin on Fri Jun 25 20:35:48 UTC 2021
PRIMARY
Related Record Type Details
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus.
EFFICACY
INHIBITOR->TARGET ORGANISM
DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.
INHIBITOR->TARGET ORGANISM
A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.
INHIBITOR->TARGET ORGANISM
In Vero E6 cells inhibits. Targets the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses. A US patient with 2019-nCoV recovered after receiving intravenous remdesivir in January
BIOASSAY (CELLULAR)
EC50
VACCINE ANTIGEN->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
The antibody binds selectively to the spike protein of SARS-CoV-2.
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis
EFFICACY
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
In Vero E6 cells
EC50
INHIBITOR->TARGET ORGANISM
nother in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.[9]
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR -> TARGET
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
TARGET ORGANISM->VACCINE ANTIGEN
AGAINST COVID DISEASE
EFFICACY
VACCINE ANTIGEN->TARGET ORGANISM
From 7 days after second dose to a median time of 2 months.
EFFICACY
INHIBITOR->TARGET ORGANISM
PART/FRACTION -> PARENT ORGANISM
INHIBITOR->TARGET ORGANISM
after 24 hours incubation; works in cell culture may not work in-vivo
EC50
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
Has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS.
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
In Vero E6 cells
EC50
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
IN-VITRO